Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 11.5% in March

Cellebrite DI Ltd. (NASDAQ:CLBTGet Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 2,620,000 shares, an increase of 11.5% from the February 29th total of 2,350,000 shares. Based on an average daily volume of 978,000 shares, the short-interest ratio is presently 2.7 days. Currently, 4.7% of the shares of the stock are sold short.

Institutional Trading of Cellebrite DI

Large investors have recently added to or reduced their stakes in the stock. IGP Investments G.P.L.P LP bought a new stake in Cellebrite DI during the fourth quarter valued at approximately $182,619,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $50,270,000. Morgan Stanley boosted its holdings in shares of Cellebrite DI by 53,737.4% during the 4th quarter. Morgan Stanley now owns 2,144,884 shares of the company’s stock valued at $9,352,000 after buying an additional 2,140,900 shares in the last quarter. Ashford Capital Management Inc. bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $12,913,000. Finally, Voss Capital LLC boosted its stake in Cellebrite DI by 207.7% in the 4th quarter. Voss Capital LLC now owns 1,835,000 shares of the company’s stock worth $15,891,000 after purchasing an additional 1,238,580 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on CLBT shares. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, March 28th. William Blair raised shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 13th. Bank of America upped their price objective on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Craig Hallum upped their target price on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI has a consensus rating of “Buy” and a consensus price target of $12.30.

Check Out Our Latest Stock Report on Cellebrite DI

Cellebrite DI Price Performance

CLBT stock traded down $0.18 during trading on Tuesday, reaching $10.83. 994,454 shares of the company were exchanged, compared to its average volume of 976,636. The company has a 50-day moving average of $10.83 and a two-hundred day moving average of $8.91. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -25.19, a P/E/G ratio of 1.95 and a beta of 1.54. Cellebrite DI has a twelve month low of $5.22 and a twelve month high of $12.50.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $93.01 million for the quarter, compared to analyst estimates of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. On average, analysts forecast that Cellebrite DI will post 0.32 EPS for the current year.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Featured Articles

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.